FINWIRES · TerminalLIVE
FINWIRES

Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19

By

Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $558.17, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles